ReviewThe FEBS journal2019
Advances and challenges in targeting IRF5, a key regulator of inflammation.
Review in The FEBS journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 112 citations in OpenAlex.
- The role of IRF5 as an immune regulator.Biochemical Society transactions · 2026Review
- Multi-trait GWAS of reaction norm parameters reveals environment-responsive loci influencing reproductive performance in heifers.Journal of animal science and biotechnology · 2026Article
- Article
- Interferon regulatory factors: the next prospective targets for tissue ischemia-reperfusion injury?Frontiers in immunology · 2026Review
- DNA methylation mediates the multiple sclerosis onset risk associated with HHV-6 DNA positivity.Environmental epigenetics · 2026Article
- Reduced Methylation of IRF5 Gene as a Biomarker for Gestational Diabetes Mellitus.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Myeloid Irf5 Deficiency Enhances the Therapeutic Efficacy of IMD-0354 in a TDP-25-Induced Neurodegeneration Model.Molecular neurobiology · 2025Article
- Genomic Structural Equation Modelling Reveals the Shared Genetic Architecture for Oral Frailty.Oral health & preventive dentistry · 2025Article
- Interferon Regulator Factor 5: A Novel Inflammatory Marker and Promising Therapeutic Target in Ulcerative Colitis.Biomedicines · 2025Article
- Article
- Peripheral transcriptional responses to experimental SARS-CoV-2 inoculation in North American elk cows and calves.BMC genomics · 2025Article
- Targeting the Dectin-1 Receptor in Neuroinflammation: Therapeutic Implications for Neuropsychiatric Disorders.ACS chemical neuroscience · 2025Review
- Covalent Degraders of Immune Regulatory Transcription Factors IRF8 and IRF5.bioRxiv : the preprint server for biology · 2025Article
- The rs3757385 polymorphism increases IRF5 expression and systemic nitric oxide metabolites, protecting urothelial bladder cancer patients from recurrence.Molecular biology reports · 2025Article
- Pleiotropic and sex-specific genetic mechanisms of circulating metabolic markers.Nature communications · 2025Article
- Disruption of the novel nested geneeLife · 2025Article
- Microglia regulate myelin clearance and cholesterol metabolism after demyelination via interferon regulatory factor 5.Cellular and molecular life sciences : CMLS · 2025Article
- CCDC134 controls TLR biogenesis through the ER chaperone Gp96.The Journal of experimental medicine · 2025Article
- Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus - focus on juvenile-onset systemic lupus erythematosus.Current opinion in rheumatology · 2025Review
- Exploring the association between Mycobacterium avium subspecies paratuberculosis infection and rheumatoid arthritis: an immunological perspective.Arthritis research & therapy · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Interferon regulatory factor 5 (IRF5) belongs to a family of transcription factors, originally implicated in antiviral responses and interferon production. However, studies conducted in different laboratories over the last decade have placed IRF5 as a central regulator of the inflammatory response. It has become clear that IRF5 contributes to the pathogenesis of many inflammatory and autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus. Given the role of IRF5 in physiology and disease, IRF5 represents a potential therapeutic target. However, despite a significant interest from the pharmaceutical industry, inhibitors that interfere with the IRF5 pathway remain elusive. Here, we review the advances made by various studies in targeting multiple steps of signalling leading to IRF5 activation with their therapeutic potential, and the possible complications of such strategies are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.